gastroesophageal cancer
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Natera Signatera MRD Test to Guide, Assess Treatment in Phase II Gastroesophageal Cancer Study
The Signatera ctDNA test will be used to evaluate the efficacy of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in the Phase II DECIPHER trial.
Castle Biosciences Builds Skin Cancer Assay Data, Eyes Future Expansion as Q1 Sales Jump 74 Percent
Premium
The company highlighted clinical research progress for its two skin cancer tests and said it hopes to expand in the gastrointestinal cancer space in coming years.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer
They plan to study the genomic, transcriptomic, and proteomic responses of gastroesophageal tumors following treatment with Merck's Keytruda.